Press releases

Regulatory press release 2022-08-05

Interim Report Second Quarter 2022

Regulatory press release 2022-06-17

Dasynoc granted Orphan Drug Designation in the US for the treatment of chronic myeloid leukemia

Regulatory press release 2022-06-15

Xspray Pharma appoints Thomas Walz as Chief Medical Officer

Press release 2022-06-09

Xspray Pharma’s long-term incentive program LTI 2022 fully subscribed

Regulatory press release 2022-05-19

Bulletin from the 2022 Annual General Meeting of Xspray Pharma AB (publ)

All press releases

Latest report
Interim Report Q2 2022
Subscribe
Get our latest press releases and reports
Subscribe
Submit to our press releases and get an email every time we publish a press release or report on our website.
Type*
Reports
Press releases
E-mail*

Välj språk*
Swedish
English
When clicked on Send I agree that my personal information will be saved. Read more
Comments
This field is for validation purposes and should be left unchanged.

Press contact

Christina Malmberg Hägerstrand, VP Communications & Investor Relations

+46 (0)72 855 93 29

christina.malmberg.hagerstrand@xspray.com

Presentations and interviews

Capital Markets Day, May 24, 2022

Interview with Per Andersson at Pareto, October 18, 2021

Interview with Per Andersson at Redeye, October 14, 2021

Media